Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention
Launched by UNIVERSITY OF MARYLAND, COLLEGE PARK · Jul 25, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help people who are struggling with opioid use and other substance use in a rural area. The study will test a peer-led program called Peer Activate, which aims to improve how well participants stick to their medication and reduce the use of other drugs. Participants will be compared to those receiving standard care to see which approach works better over a year.
To be eligible for the study, participants must be 18 years or older, currently receiving treatment for opioid use disorder through a telemedicine program, and have used other substances (besides opioids and tobacco) in the last three months. It's important to note that individuals with severe psychiatric issues that are not being treated and those who cannot understand the study in English cannot participate. Those who join can expect to receive support from trained peers who understand their challenges and can help guide them through their recovery journey.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient participants in the RCT must be 18 or older; receive OUD treatment as part of the telemedicine program; and exhibit polysubstance use within the past three-months (i.e., use of one or more non-prescribed substances (excluding opioids and/or tobacco) by urine toxicology or self-report.
- Exclusion Criteria:
- • Demonstrating active, unstable or untreated psychiatric symptoms, including mania and/or psychosis that would interfere with study participation
- • Inability to understand the study and provide informed consent in English
About University Of Maryland, College Park
The University of Maryland, College Park, is a leading research institution dedicated to advancing knowledge and innovation in various fields, including health and medicine. As a prominent clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and commitment to rigorous scientific inquiry to facilitate impactful clinical research. The institution fosters collaborations among faculty, healthcare professionals, and industry partners to enhance patient care and drive advancements in medical science, ensuring compliance with ethical standards and regulatory requirements throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
College Park, Maryland, United States
Baltimore, Maryland, United States
Denton, Maryland, United States
Patients applied
Trial Officials
Jessica F Magidson, PhD
Principal Investigator
University of Maryland, College Park
Sarah M Kattakuzhy, MD
Principal Investigator
University of Maryland, Baltimore
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported